Ziprasidone (BioDeep_00000402569)

Main id: BioDeep_00000001913

 


代谢物信息卡片


Ziprasidone

化学式: C21H21ClN4OS (412.1125)
中文名称: 齐拉西酮
谱图信息: 最多检出来源 Homo sapiens(urine) 23.68%

分子结构信息

SMILES: c1ccc2c(c1)c(ns2)N1CCN(CCc2cc3CC(=O)Nc3cc2Cl)CC1
InChI: InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)

描述信息

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AE - Indole derivatives
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
CONFIDENCE standard compound; INTERNAL_ID 2747
CONFIDENCE standard compound; INTERNAL_ID 8529
Ziprasidone (CP-88059), an orally active antipsychotic agent, is a combined 5-HT and dopamine receptor antagonist[1]. Ziprasidone mesylate trihydrate has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM)[1].

同义名列表

3 个代谢物同义名

Ziprasidone; CP-88059; Ziprasidone



数据库引用编号

20 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 7 ABCB1, AXIN2, BDNF, CYP2C19, CYP2D6, CYP3A4, SLC6A3
Endoplasmic reticulum membrane 4 CYP1A2, CYP2C19, CYP2D6, CYP3A4
Nucleus 1 AXIN2
cytosol 3 AXIN2, GSR, LEP
dendrite 6 BDNF, DRD2, HTR1A, HTR1D, HTR2A, HTR2C
centrosome 1 AXIN2
Cell membrane 9 ABCB1, DRD2, HTR1A, HTR1D, HTR2A, HTR2C, KCNH2, SLC6A3, TNF
Cell projection, axon 2 HTR2A, SLC6A3
Multi-pass membrane protein 9 ABCB1, DRD2, HTR1A, HTR1D, HTR2A, HTR2C, KCNH2, NNT, SLC6A3
Golgi apparatus membrane 1 DRD2
Synapse 4 DRD2, HTR1A, HTR1D, HTR2C
cell surface 4 ABCB1, KCNH2, SLC6A3, TNF
dendritic shaft 1 HTR2A
glutamatergic synapse 2 DRD2, HTR2A
Golgi membrane 2 DRD2, INS
mitochondrial inner membrane 1 NNT
neuronal cell body 3 HTR2A, SLC6A3, TNF
presynaptic membrane 3 DRD2, HTR2A, SLC6A3
synaptic vesicle 1 BDNF
Presynapse 1 HTR2A
acrosomal vesicle 1 DRD2
plasma membrane 11 ABCB1, AXIN2, CYP2C19, DRD2, HTR1A, HTR1D, HTR2A, HTR2C, KCNH2, SLC6A3, TNF
synaptic vesicle membrane 1 DRD2
Membrane 7 ABCB1, BDNF, CYP2D6, CYP3A4, KCNH2, NNT, SLC6A3
apical plasma membrane 1 ABCB1
axon 4 BDNF, DRD2, HTR2A, SLC6A3
caveola 1 HTR2A
extracellular exosome 2 ABCB1, GSR
endoplasmic reticulum 1 CYP2D6
extracellular space 5 BDNF, IL6, INS, LEP, TNF
perinuclear region of cytoplasm 2 BDNF, KCNH2
mitochondrion 3 CYP2D6, GSR, NNT
intracellular membrane-bounded organelle 4 CYP1A2, CYP2C19, CYP2D6, CYP3A4
Microsome membrane 3 CYP1A2, CYP2D6, CYP3A4
Secreted 4 BDNF, IL6, INS, LEP
extracellular region 5 BDNF, IL6, INS, LEP, TNF
Single-pass membrane protein 1 CYP2D6
neuronal cell body membrane 1 SLC6A3
mitochondrial matrix 1 GSR
ciliary membrane 1 DRD2
external side of plasma membrane 2 GSR, TNF
dendritic spine 1 DRD2
perikaryon 1 DRD2
beta-catenin destruction complex 1 AXIN2
cytoplasmic vesicle 1 HTR2A
recycling endosome 1 TNF
Single-pass type II membrane protein 1 TNF
postsynaptic membrane 3 DRD2, HTR2A, SLC6A3
Apical cell membrane 1 ABCB1
Mitochondrion inner membrane 1 NNT
Matrix side 1 NNT
Membrane raft 2 SLC6A3, TNF
GABA-ergic synapse 1 DRD2
flotillin complex 1 SLC6A3
lateral plasma membrane 1 DRD2
Cell projection, neuron projection 1 SLC6A3
neuron projection 1 SLC6A3
cilium 1 DRD2
phagocytic cup 1 TNF
non-motile cilium 1 DRD2
sperm flagellum 1 DRD2
endosome lumen 1 INS
Membrane, caveola 1 HTR2A
monoatomic ion channel complex 1 KCNH2
cell body fiber 1 HTR2A
Cell projection, dendrite 2 HTR1A, HTR2A
respiratory chain complex 1 NNT
inward rectifier potassium channel complex 1 KCNH2
voltage-gated potassium channel complex 1 KCNH2
secretory granule lumen 1 INS
Golgi lumen 1 INS
endoplasmic reticulum lumen 3 BDNF, IL6, INS
axon terminus 2 DRD2, SLC6A3
endocytic vesicle 1 DRD2
transport vesicle 1 INS
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
neurofilament 1 HTR2A
external side of apical plasma membrane 1 ABCB1
dopaminergic synapse 2 DRD2, SLC6A3
[Tumor necrosis factor, soluble form]: Secreted 1 TNF
interleukin-6 receptor complex 1 IL6
G protein-coupled receptor complex 1 DRD2
[Neurotrophic factor BDNF precursor form]: Secreted 1 BDNF
G protein-coupled serotonin receptor complex 2 HTR2A, HTR2C
[C-domain 2]: Secreted 1 TNF
[Tumor necrosis factor, membrane form]: Membrane 1 TNF
[C-domain 1]: Secreted 1 TNF


文献列表

  • Marco Pozzi, Chiara Vantaggiato, Francesca Brivio, Genny Orso, Maria Teresa Bassi. Olanzapine, risperidone and ziprasidone differently affect lysosomal function and autophagy, reflecting their different metabolic risk in patients. Translational psychiatry. 2024 Jan; 14(1):13. doi: 10.1038/s41398-023-02686-x. [PMID: 38191558]
  • Ankita Sahu, Shaban Ahmad, Khalid Imtiyaz, Ajeeshkumar Kizhakkeppurath Kumaran, Mojahidul Islam, Khalid Raza, Murugesh Easwaran, Asha Kurukkan Kunnath, Moshahid A Rizvi, Saurabh Verma. In-silico and in-vitro study reveals ziprasidone as a potential aromatase inhibitor against breast carcinoma. Scientific reports. 2023 10; 13(1):16545. doi: 10.1038/s41598-023-43789-1. [PMID: 37783782]
  • Hannah M Ficarino, Michael Z Caposole, S Noelle Davis, Mackenzie N Krebsbach, Emily F McGowin, Kaitlin M Alexander, Christopher M Kinnard, Jon D Simmons. Neuroleptic Malignant Syndrome: A Potential Etiology of Multisystem Organ Failure in a Burn Patient. The American surgeon. 2022 Mar; 88(3):519-520. doi: 10.1177/0003134820945245. [PMID: 32988244]
  • Yub Raj Sedhai, Alok Atreya, Prabin Phuyal, Soney Basnyat, Sagar Pokhrel. Case Report: Ziprasidone induced neuroleptic malignant syndrome. F1000Research. 2021; 10(?):124. doi: 10.12688/f1000research.51094.1. [PMID: 33763203]
  • Javier Vázquez-Bourgon, Miguel Ibáñez Alario, Jacqueline Mayoral-van Son, Marcos Gómez Revuelta, Rosa Ayesa Arriola, María Juncal Ruiz, Víctor Ortiz-García de la Foz, Benedicto Crespo Facorro. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2020 10; 39(?):46-55. doi: 10.1016/j.euroneuro.2020.08.009. [PMID: 32891516]
  • Margo R Rollins, Judith Deeter, Charlene D Banks, Pam Langley. New onset metabolic derangement in a pediatric patient receiving therapeutic plasma exchange for anti-NMDA receptor encephalitis. Journal of clinical apheresis. 2020 Apr; 35(2):125-127. doi: 10.1002/jca.21768. [PMID: 32027046]
  • Jakub Staroń, Rafał Kurczab, Dawid Warszycki, Grzegorz Satała, Martyna Krawczyk, Ryszard Bugno, Tomasz Lenda, Piotr Popik, Adam S Hogendorf, Agata Hogendorf, Krzysztof Dubiel, Mikołaj Matłoka, Rafał Moszczyński-Pętkowski, Jerzy Pieczykolan, Maciej Wieczorek, Paweł Zajdel, Andrzej J Bojarski. Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties. European journal of medicinal chemistry. 2020 Jan; 185(?):111857. doi: 10.1016/j.ejmech.2019.111857. [PMID: 31734022]
  • Urooj A Khan, Uzma Parveen, Nazeer Hasan, Mohammad Zubair Ahmed, Suma Saad, Farhan J Ahmad, Gaurav K Jain. Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy. Drug design, development and therapy. 2020; 14(?):2237-2247. doi: 10.2147/dddt.s247196. [PMID: 32606594]
  • Tamara N Uzelac, Aleksandra L Nikolić-Kokić, Snežana D Spasić, Mirjana T Mačvanin, Milan R Nikolić, Ljuba M Mandić, Vesna B Jovanović. Opposite clozapine and ziprasidone effects on the reactivity of plasma albumin SH-group are the consequence of their different binding properties dependent on protein fatty acids content. Chemico-biological interactions. 2019 Sep; 311(?):108787. doi: 10.1016/j.cbi.2019.108787. [PMID: 31400341]
  • Wei Wang, Mengru Bai, Ting Jiang, Cui Li, Ping Li, Hui Zhou, Zemin Wang, Liping Li, Huidi Jiang. Clozapine-induced reduction of l-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice. Toxicology and applied pharmacology. 2019 01; 363(?):47-56. doi: 10.1016/j.taap.2018.11.007. [PMID: 30465787]
  • Tahlia R Meola, Tahnee J Dening, Clive A Prestidge. Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone in vitro. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2018 Aug; 129(?):145-153. doi: 10.1016/j.ejpb.2018.05.028. [PMID: 29857135]
  • Anna Dietrich-Muszalska, Jolanta Kolińska-Łukaszuk. Comparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma. Psychiatry and clinical neurosciences. 2018 May; 72(5):329-336. doi: 10.1111/pcn.12631. [PMID: 29280533]
  • Javier Vázquez-Bourgon, Rocío Pérez-Iglesias, Víctor Ortiz-García de la Foz, Paula Suárez Pinilla, Álvaro Díaz Martínez, Benedicto Crespo-Facorro. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. Psychopharmacology. 2018 01; 235(1):245-255. doi: 10.1007/s00213-017-4763-x. [PMID: 29075885]
  • Benedicto Crespo-Facorro, Victor Ortiz-Garcia de la Foz, Paula Suarez-Pinilla, Elsa M Valdizan, Rocío Pérez-Iglesias, Jose Antonio Amado-Señaris, M Teresa Garcia-Unzueta, Javier Labad, Christopher Correll, Rosa Ayesa-Arriola. Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study. Schizophrenia research. 2017 11; 189(?):134-141. doi: 10.1016/j.schres.2017.01.046. [PMID: 28223031]
  • Shao-Ting Wang, Yan Li. Development of a UPLC-MS/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients. Biomedical chromatography : BMC. 2017 Aug; 31(8):. doi: 10.1002/bmc.3928. [PMID: 28054367]
  • Huai-Hai Wang, Min Cai, Hua-Ning Wang, Yun-Chun Chen, Rui-Guo Zhang, Ying Wang, Grainne M McAlonan, Yuan-Han Bai, Wen-Jun Wu, Li Guo, Ya-Hong Zhang, Qing-Rong Tan, Zhang-Jin Zhang. An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders. Journal of psychiatric research. 2017 02; 85(?):59-65. doi: 10.1016/j.jpsychires.2016.11.002. [PMID: 27837658]
  • Tahnee J Dening, Shasha Rao, Nicky Thomas, Clive A Prestidge. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2016 Apr; 101(?):33-42. doi: 10.1016/j.ejpb.2016.01.010. [PMID: 26812284]
  • Aleksandra Nikolić-Kokić, Ana Mijušković, Nikola Tatalović, Jelena Nestorov, Marko Miler, Zorana Oreščanin-Dušić, Milan Nikolić, Verica Milošević, Duško Blagojević, Mihajlo Spasić, Čedo Miljević. Effects of antipsychotic drug administration on antioxidative defense enzymes in male rat kidney. Journal of toxicology and environmental health. Part A. 2016; 79(20):905-11. doi: 10.1080/15287394.2016.1201706. [PMID: 27644343]
  • Hriday Bera, Shashank Boddupalli, Amit Kumar Nayak. Mucoadhesive-floating zinc-pectinate-sterculia gum interpenetrating polymer network beads encapsulating ziprasidone HCl. Carbohydrate polymers. 2015 Oct; 131(?):108-18. doi: 10.1016/j.carbpol.2015.05.042. [PMID: 26256166]
  • Joseph W Iskandar, John Eric Vance, Anita Kablinger, Bush Kavuru. Transient agranulocytosis associated with ziprasidone in a 45-year-old man on hemodialysis. Journal of clinical psychopharmacology. 2015 Jun; 35(3):347-8. doi: 10.1097/jcp.0000000000000324. [PMID: 25874914]
  • Piotr Tybura, Beata Trześniowska-Drukała, Przemyslaw Bienkowski, Aleksander Beszlej, Dorota Frydecka, Pawel Mierzejewski, Agnieszka Samochowiec, Anna Grzywacz, Jerzy Samochowiec. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine. Psychiatry research. 2014 Oct; 219(2):261-7. doi: 10.1016/j.psychres.2014.05.039. [PMID: 24930580]
  • Rocio Pérez-Iglesias, Victor Ortiz-Garcia de la Foz, Obdulia Martínez García, Jose Antonio Amado, M Teresa Garcia-Unzueta, Rosa Ayesa-Arriola, Paula Suarez-Pinilla, Rafael Tabares-Seisdedos, Benedicto Crespo-Facorro. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. Schizophrenia research. 2014 Oct; 159(1):90-4. doi: 10.1016/j.schres.2014.07.045. [PMID: 25151200]
  • Mona Darwish, Mary Bond, Ronghua Yang, Edward T Hellriegel, Philmore Robertson. Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. Clinical drug investigation. 2014 Oct; 34(10):691-9. doi: 10.1007/s40261-014-0220-3. [PMID: 25047407]
  • Pierre Chue, Francine S Mandel, François Therrien. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study. Current medical research and opinion. 2014 Jun; 30(6):997-1005. doi: 10.1185/03007995.2014.898139. [PMID: 24568177]
  • Laura Mercolini, Roberto Mandrioli, Michele Protti, Andreas Conca, Lawrence J Albers, Maria Augusta Raggi. Dried blood spot testing: a novel approach for the therapeutic drug monitoring of ziprasidone-treated patients. Bioanalysis. 2014 Jun; 6(11):1487-95. doi: 10.4155/bio.14.3. [PMID: 25046049]
  • Laura Mercolini, Michele Protti, Giulia Fulgenzi, Roberto Mandrioli, Nadia Ghedini, Andreas Conca, Maria Augusta Raggi. A fast and feasible microextraction by packed sorbent (MEPS) procedure for HPLC analysis of the atypical antipsychotic ziprasidone in human plasma. Journal of pharmaceutical and biomedical analysis. 2014 Jan; 88(?):467-71. doi: 10.1016/j.jpba.2013.09.019. [PMID: 24176751]
  • Hwang-Bin Lee, Bo-Hyun Yoon, Young-Joon Kwon, Young Sup Woo, Jung-Goo Lee, Moon-Doo Kim, Won-Myong Bahk. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study. Clinical drug investigation. 2013 Oct; 33(10):743-53. doi: 10.1007/s40261-013-0120-y. [PMID: 23990283]
  • Sho Moriguchi, Robert R Bies, Gary Remington, Takefumi Suzuki, David C Mamo, Koichiro Watanabe, Masaru Mimura, Bruce G Pollock, Hiroyuki Uchida. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data. Journal of clinical psychopharmacology. 2013 Oct; 33(5):682-5. doi: 10.1097/jcp.0b013e3182979a0a. [PMID: 23899638]
  • Donald C Goff, Joseph P McEvoy, Leslie Citrome, Arnold W Mech, Juan R Bustillo, Roberto Gil, Peter Buckley, Theo C Manschreck, Eric D Achtyes, Eric A Macklin. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. Journal of clinical psychopharmacology. 2013 Aug; 33(4):485-90. doi: 10.1097/jcp.0b013e3182977308. [PMID: 23775057]
  • Takashi Tsuboi, Robert R Bies, Takefumi Suzuki, David C Mamo, Bruce G Pollock, Ariel Graff-Guerrero, Masaru Mimura, Hiroyuki Uchida. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Progress in neuro-psychopharmacology & biological psychiatry. 2013 Aug; 45(?):178-82. doi: 10.1016/j.pnpbp.2013.05.010. [PMID: 23727135]
  • D Holthoewer, K M Kirschbaum, J Frisch, C Hiemke, U Schmitt. Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties. Pharmacopsychiatry. 2013 Jul; 46(5):175-80. doi: 10.1055/s-0033-1347176. [PMID: 23737243]
  • Anna Dietrich-Muszalska, Justyna Kopka, Anna Kwiatkowska. The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison. Neurochemical research. 2013 Jul; 38(7):1490-5. doi: 10.1007/s11064-013-1050-z. [PMID: 23619559]
  • Hitoshi Sakurai, Robert R Bies, Scott T Stroup, Richard S E Keefe, Tarek K Rajji, Takefumi Suzuki, David C Mamo, Bruce G Pollock, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchida. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophrenia bulletin. 2013 May; 39(3):564-74. doi: 10.1093/schbul/sbr189. [PMID: 22290266]
  • Ping Shao, Jianjun Ou, Renrong Wu, Maosheng Fang, Honghui Chen, Yi Xu, Jingping Zhao. [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. 2013 Apr; 38(4):365-9. doi: 10.3969/j.issn.1672-7347.2013.04.005. [PMID: 23645236]
  • Jian-Jun Ou, Yi Xu, Hong-Hui Chen, Xiaoduo Fan, Keming Gao, Juan Wang, Xiao-Feng Guo, Ren-Rong Wu, Jing-Ping Zhao. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology. 2013 Feb; 225(3):627-35. doi: 10.1007/s00213-012-2850-6. [PMID: 22926006]
  • Andrew J Cutler, Amir H Kalali, Greg W Mattingly, Jelena Kunovac, Xiangyi Meng. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS spectrums. 2013 Feb; 18(1):43-54. doi: 10.1017/s1092852912000764. [PMID: 23312567]
  • Priscila Gubert, Gabriel Costa Aguiar, Tácito Mourão, Jessika Cristina Bridi, Alexandre Guimarães Barros, Félix Alexandre Soares, Marco Aurélio Romano-Silva. Behavioral and metabolic effects of the atypical antipsychotic ziprasidone on the nematode Caenorhabditis elegans. PloS one. 2013; 8(9):e74780. doi: 10.1371/journal.pone.0074780. [PMID: 24069346]
  • David N Osser, Mohsen Jalali Roudsari, Theo Manschreck. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harvard review of psychiatry. 2013 Jan; 21(1):18-40. doi: 10.1097/hrp.0b013e31827fd915. [PMID: 23656760]
  • Yinbo Zhang, Guangzhi Dai. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Human psychopharmacology. 2012 Nov; 27(6):605-14. doi: 10.1002/hup.2270. [PMID: 24446539]
  • Swapnil Marghade, Prashant B Musmade, Sudheer Moorkoth. High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. Journal of chromatographic science. 2012 Nov; 50(10):902-8. doi: 10.1093/chromsci/bms088. [PMID: 22677485]
  • Rui-Ming Li, Cong Wang, Zhi-Wei Liu, Bin Zhao. A case of severe hyponatremia induced by duloxetine and ziprasidone. Chinese medical journal. 2012 Oct; 125(20):3750-1. doi: . [PMID: 23075738]
  • Yasuhisa Nagasaka, Kazuo Oda, Takafumi Iwatsubo, Akio Kawamura, Takashi Usui. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier. Biopharmaceutics & drug disposition. 2012 Sep; 33(6):304-15. doi: 10.1002/bdd.1801. [PMID: 22847220]
  • Tong Zhao, Tae-Won Park, Jong-Chul Yang, Guang-Biao Huang, Min-Gul Kim, Keon-Hak Lee, Young-Chul Chung. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial. International clinical psychopharmacology. 2012 Jul; 27(4):184-90. doi: 10.1097/yic.0b013e3283528d22. [PMID: 22426471]
  • Elizabeth Pappadopulos, John W Newcomer, Sheela Kolluri. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials. The Journal of clinical psychiatry. 2012 Jun; 73(6):e742-8. doi: 10.4088/jcp.10r06802. [PMID: 22795213]
  • X L Wu, J H Wang, S H Hu, J Tao. Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version). East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan. 2012 Mar; 22(1):7-11. doi: NULL. [PMID: 22447799]
  • Yongfeng Yang, Wenqiang Li, Jingyuan Zhao, Hongxing Zhang, Xueqin Song, Bo Xiao, Ge Yang, Chengdi Jiang, Dai Zhang, Weihua Yue, Luxian Lv. Association between ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients. Behavioral and brain functions : BBF. 2012 Feb; 8(?):11. doi: 10.1186/1744-9081-8-11. [PMID: 22369141]
  • Goran Jassim, Silje Skrede, María Jesús Vázquez, Hege Wergedal, Audun O Vik-Mo, Niclas Lunder, Carlos Diéguez, Antonio Vidal-Puig, Rolf K Berge, Miguel López, Vidar M Steen, Johan Fernø. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology. 2012 Feb; 219(3):783-94. doi: 10.1007/s00213-011-2397-y. [PMID: 21748251]
  • Vance L Albaugh, Thomas C Vary, Olga Ilkayeva, Brett R Wenner, Kevin P Maresca, John L Joyal, Steven Breazeale, Tedd D Elich, Charles H Lang, Christopher J Lynch. Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. Schizophrenia bulletin. 2012 Jan; 38(1):153-66. doi: 10.1093/schbul/sbq053. [PMID: 20494946]
  • Laura Gedge, Ashley Beaudoin, Lauren Lazowski, Regina du Toit, Ruzica Jokic, Roumen Milev. Effects of electroconvulsive therapy and repetitive transcranial magnetic stimulation on serum brain-derived neurotrophic factor levels in patients with depression. Frontiers in psychiatry. 2012; 3(?):12. doi: 10.3389/fpsyt.2012.00012. [PMID: 22375129]
  • Lawrence Maayan, Christoph U Correll. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of child and adolescent psychopharmacology. 2011 Dec; 21(6):517-35. doi: 10.1089/cap.2011.0015. [PMID: 22166172]
  • Andréa L Sertié, Angela May Suzuki, Rogério A L Sertié, Sandra Andreotti, Fábio B Lima, Maria Rita Passos-Bueno, Wagner F Gattaz. Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism. Progress in neuro-psychopharmacology & biological psychiatry. 2011 Dec; 35(8):1884-90. doi: 10.1016/j.pnpbp.2011.07.017. [PMID: 21840366]
  • Kyeong-Ryoon Lee, Yoon-Jee Chae, Tae-Sung Koo. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. Xenobiotica; the fate of foreign compounds in biological systems. 2011 Dec; 41(12):1100-7. doi: 10.3109/00498254.2011.603388. [PMID: 21838595]
  • Tae-Sung Koo, Soo-Jin Kim, Jongjoo Lee, Dong-Jin Ha, Myoungki Baek, Hongsik Moon. Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry. Biomedical chromatography : BMC. 2011 Dec; 25(12):1389-94. doi: 10.1002/bmc.1625. [PMID: 21387355]
  • R T Owen. Lurasidone: a new treatment option for schizophrenia. Drugs of today (Barcelona, Spain : 1998). 2011 Nov; 47(11):807-16. doi: 10.1358/dot.2011.47.11.1708832. [PMID: 22146224]
  • Adrian Newman-Tancredi, Mark S Kleven. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology. 2011 Aug; 216(4):451-73. doi: 10.1007/s00213-011-2247-y. [PMID: 21394633]
  • Tim Moons, Mariska de Roo, Stephan Claes, Geert Dom. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics. 2011 Aug; 12(8):1193-211. doi: 10.2217/pgs.11.55. [PMID: 21843066]
  • Christoph U Correll, Johnny D Lops, Vicki Figen, Anil K Malhotra, John M Kane, Peter Manu. QT interval duration and dispersion in children and adolescents treated with ziprasidone. The Journal of clinical psychiatry. 2011 Jun; 72(6):854-60. doi: 10.4088/jcp.10m05990yel. [PMID: 21457682]
  • W Gordon Frankle, Ilise Lombardo, Lawrence S Kegeles, Mark Slifstein, John H Martin, Yiyun Huang, Dah-Ren Hwang, Elisa Reich, Claudine Cangiano, Roberto Gil, Anissa Abi-Dargham, Marc Laruelle. Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone. Journal of psychopharmacology (Oxford, England). 2011 Jun; 25(6):734-43. doi: 10.1177/0269881110388329. [PMID: 21109614]
  • Marija Bošković, Tomaž Vovk, Blanka Kores Plesničar, Iztok Grabnar. Oxidative stress in schizophrenia. Current neuropharmacology. 2011 Jun; 9(2):301-12. doi: 10.2174/157015911795596595. [PMID: 22131939]
  • Hiroyuki Uchida, Hiroyoshi Takeuchi, Ariel Graff-Guerrero, Takefumi Suzuki, Koichiro Watanabe, David C Mamo. Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. Journal of clinical psychopharmacology. 2011 Jun; 31(3):318-25. doi: 10.1097/jcp.0b013e318218d339. [PMID: 21508857]
  • Parminder S Chaggar, Steven M Shaw, Simon G Williams. Effect of antipsychotic medications on glucose and lipid levels. Journal of clinical pharmacology. 2011 May; 51(5):631-8. doi: 10.1177/0091270010368678. [PMID: 20410451]
  • Eric Hermes, Henry Nasrallah, Vicki Davis, Jonathan Meyer, Joseph McEvoy, Donald Goff, Sonia Davis, T Scott Stroup, Marvin Swartz, Jeffrey Lieberman, Robert Rosenheck. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophrenia research. 2011 May; 128(1-3):166-70. doi: 10.1016/j.schres.2011.01.022. [PMID: 21334853]
  • Onur N Karayal, Paul Glue, Mary Bachinsky, Michelle Stewart, Phillip Chappell, Sheela Kolluri, Idil Cavus. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. Journal of psychiatric practice. 2011 Mar; 17(2):100-9. doi: 10.1097/01.pra.0000396061.05269.c8. [PMID: 21430488]
  • Edwin Lee, Lai-Yin Chow, Chi-Ming Leung. Metabolic profile of first and second generation antipsychotics among Chinese patients. Psychiatry research. 2011 Feb; 185(3):456-8. doi: 10.1016/j.psychres.2010.04.050. [PMID: 20554016]
  • Sally A Arif, Melissa M Mitchell. Iloperidone: A new drug for the treatment of schizophrenia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2011 Feb; 68(4):301-8. doi: 10.2146/ajhp100079. [PMID: 21289324]
  • H Y Meltzer, B W Massey. The role of serotonin receptors in the action of atypical antipsychotic drugs. Current opinion in pharmacology. 2011 Feb; 11(1):59-67. doi: 10.1016/j.coph.2011.02.007. [PMID: 21420906]
  • Robert G Bota, Allein P Ligasan, Tom G Najdowski, Andrei Novac. Acute hypersensitivity syndrome caused by valproic Acid: a review of the literature and a case report. The Permanente journal. 2011; 15(2):80-4. doi: 10.7812/tpp/10-140. [PMID: 21841930]
  • Jørgen Hasselstrøm. Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2011 Jan; 879(1):123-8. doi: 10.1016/j.jchromb.2010.11.024. [PMID: 21163713]
  • M Soledad García, Joaquín A Ortuño, María Cuartero, Mustafa Salem Abuherba. Use of a new ziprasidone-selective electrode in mixed solvents and its application in the analysis of pharmaceuticals and biological fluids. Sensors (Basel, Switzerland). 2011; 11(9):8813-25. doi: 10.3390/s110908813. [PMID: 22164107]
  • Vance L Albaugh, Ravi Singareddy, David Mauger, Christopher J Lynch. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PloS one. 2011; 6(8):e22662. doi: 10.1371/journal.pone.0022662. [PMID: 21857944]
  • Leslie Citrome. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert opinion on drug metabolism & toxicology. 2010 Dec; 6(12):1551-64. doi: 10.1517/17425255.2010.531259. [PMID: 21034370]
  • Hongying Gao, Shibing Deng, R Scott Obach. A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments. Drug metabolism and disposition: the biological fate of chemicals. 2010 Dec; 38(12):2147-56. doi: 10.1124/dmd.110.034637. [PMID: 20847138]
  • Ann E Maloney, Linmarie Sikich. Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatric disease and treatment. 2010 Nov; 6(?):749-66. doi: 10.2147/ndt.s6614. [PMID: 21127693]
  • Virginia L Stauffer, Jennifer L Sniadecki, Kevin W Piezer, Jennifer Gatz, Sara Kollack-Walker, Vicki Poole Hoffmann, Robert Conley, Todd Durell. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. BMC psychiatry. 2010 Nov; 10(?):89. doi: 10.1186/1471-244x-10-89. [PMID: 21047395]
  • Ming-Hong Hsieh, Wei-Wen Lin, Shao-Tsu Chen, Kao-Ching Chen, Kuang-Peng Chen, Nan-Ying Chiu, Chao Huang, Ching-Jui Chang, Cheng-Hsiu Lin, Te-Jen Lai. A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting. Annals of general psychiatry. 2010 Sep; 9(?):35. doi: 10.1186/1744-859x-9-35. [PMID: 20849577]
  • Svein I Johannessen, Cecilie Johannessen Landmark. Antiepileptic drug interactions - principles and clinical implications. Current neuropharmacology. 2010 Sep; 8(3):254-67. doi: 10.2174/157015910792246254. [PMID: 21358975]
  • Raymond A Lorenz, Cherry W Jackson, Marianne Saitz. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy. 2010 Sep; 30(9):942-51. doi: 10.1592/phco.30.9.942. [PMID: 20795849]
  • E N Rizos, S Chatziioannou, N Siafakas, A Douzenis, E Katsantoni, A Mandrapilia, S Bacalis, C Fotiadis, L Lykouras. Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report. Progress in neuro-psychopharmacology & biological psychiatry. 2010 Aug; 34(6):1135-6. doi: 10.1016/j.pnpbp.2010.05.001. [PMID: 20460141]
  • Roger S McIntyre, Lael Cragin, Sonja Sorensen, Huseyin Naci, Tim Baker, Jean-Pascal Roussy. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. Journal of evaluation in clinical practice. 2010 Aug; 16(4):744-55. doi: 10.1111/j.1365-2753.2009.01189.x. [PMID: 20545800]
  • Jen-Tzer Gau, Utkarsh Acharya, Salman Khan, Victor Heh, Lona Mody, Tzu-Cheg Kao. Pharmacotherapy and the risk for community-acquired pneumonia. BMC geriatrics. 2010 Jul; 10(?):45. doi: 10.1186/1471-2318-10-45. [PMID: 20604960]
  • J J Sheehan, J K Sliwa, J C Amatniek, A Grinspan, C M Canuso. Atypical antipsychotic metabolism and excretion. Current drug metabolism. 2010 Jul; 11(6):516-25. doi: 10.2174/138920010791636202. [PMID: 20540690]
  • Dilek Kul, Mehmet Gumustas, Bengi Uslu, Sibel A Ozkan. Electroanalytical characteristics of antipsychotic drug ziprasidone and its determination in pharmaceuticals and serum samples on solid electrodes. Talanta. 2010 Jun; 82(1):286-95. doi: 10.1016/j.talanta.2010.04.036. [PMID: 20685469]
  • Vasilios G Masdrakis, Andreas Florakis, Georgios Tzanoulinos, Maria Markatou, Panagiotis Oulis. Safety of the electroconvulsive therapy-ziprasidone combination. The journal of ECT. 2010 Jun; 26(2):139-42. doi: 10.1097/yct.0b013e3181c1880e. [PMID: 20386116]
  • Chip Gresham, Anne M Ruha. Respiratory failure following isolated ziprasidone ingestion in a toddler. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2010 Mar; 6(1):41-3. doi: 10.1007/s13181-010-0035-4. [PMID: 20213216]
  • Yvette E Savoy, Michael A Ashton, Matthew W Miller, Frank M Nedza, Douglas K Spracklin, Mark H Hawthorn, Hans Rollema, F Fatima Matos, Eva Hajos-Korcsok. Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation. Schizophrenia bulletin. 2010 Mar; 36(2):410-8. doi: 10.1093/schbul/sbn104. [PMID: 18703666]
  • Jeffrey J Miceli, Thomas G Tensfeldt, Thomas Shiovitz, Richard Anziano, Cedric O'Gorman, Rachel H Harrigan. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder. Pharmacotherapy. 2010 Feb; 30(2):127-35. doi: 10.1592/phco.30.2.127. [PMID: 20099987]
  • Arlan L Rosenbloom. Hyperprolactinemia with antipsychotic drugs in children and adolescents. International journal of pediatric endocrinology. 2010; 2010(?):. doi: 10.1155/2010/159402. [PMID: 20871665]
  • Elaine H Morrato, Benjamin Druss, Daniel M Hartung, Robert J Valuck, Richard Allen, Elizabeth Campagna, John W Newcomer. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Archives of general psychiatry. 2010 Jan; 67(1):17-24. doi: 10.1001/archgenpsychiatry.2009.179. [PMID: 20048219]
  • Gavin P Reynolds, Shona L Kirk. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacology & therapeutics. 2010 Jan; 125(1):169-79. doi: 10.1016/j.pharmthera.2009.10.010. [PMID: 19931306]
  • Johann Steiner, Aye Mu Myint, Kolja Schiltz, Sabine Westphal, Hans-Gert Bernstein, Martin Walter, Matthias L Schroeter, Markus J Schwarz, Bernhard Bogerts. S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance. Cardiovascular psychiatry and neurology. 2010; 2010(?):480707. doi: 10.1155/2010/480707. [PMID: 20631894]
  • Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira. Safety and tolerability of antipsychotics: focus on amisulpride. Drug, healthcare and patient safety. 2010; 2(?):205-11. doi: 10.2147/dhps.s6226. [PMID: 21701632]
  • R Miller. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. Current neuropharmacology. 2009 Dec; 7(4):315-30. doi: 10.2174/157015909790031184. [PMID: 20514211]
  • S Chabroux, E Haffen, A Penfornis. [Diabetes and second-generation (atypical) antipsychotics]. Annales d'endocrinologie. 2009 Sep; 70(4):202-10. doi: 10.1016/j.ando.2009.07.003. [PMID: 19700142]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • Guang-fa Wang, Qing-xia Chen, Wei-qiao Huang, Wei-zhong Liu, Jia-jie Zhang. [Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2009 Aug; 29(8):1561-4. doi: NULL. [PMID: 19726292]
  • Viktoria Simon, Ruud van Winkel, Marc De Hert. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. The Journal of clinical psychiatry. 2009 Jul; 70(7):1041-50. doi: 10.4088/jcp.08r04392. [PMID: 19653979]
  • Gerald M Reaven, Jeffrey A Lieberman, Gopalan Sethuraman, Helena Kraemer, John M Davis, Christine Blasey, Ming T Tsuang, Alan F Schatzberg. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. Journal of psychiatric research. 2009 Jul; 43(11):997-1002. doi: 10.1016/j.jpsychires.2009.01.010. [PMID: 19268968]
  • Elaine H Morrato, John W Newcomer, Siddhesh Kamat, Onur Baser, James Harnett, Brian Cuffel. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes care. 2009 Jun; 32(6):1037-42. doi: 10.2337/dc08-1720. [PMID: 19244091]
  • Mathias Zink, A Kuwilsky, B Krumm, H Dressing. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. Journal of psychopharmacology (Oxford, England). 2009 May; 23(3):305-14. doi: 10.1177/0269881108089593. [PMID: 18562423]